FINLEE 10 mg, dispersible tablet 210 tablets
Active ingredients: DABRAFÉNIB, Dabrafenib mesylate
Commercialized according to BDPMDispensing in France: Prescription only
Dispersible tablet210 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- FINLEE 10 mg, comprimé dispersible
- Pharmaceutical form
- comprimé dispersible
- Route of administration
- orale
- Presentation description
- 1 flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 210 comprimé(s) avec 2 gobelet(s) doseur(s)
- Marketing authorisation holder
- NOVARTIS EUROPHARM (IRLANDE)
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 13 May 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61606482CIP73028119CIP133400930281192Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| DABRAFÉNIBcomprimé | 10 mg · un comprimé | FT |
| MÉSILATE DE DABRAFÉNIBcomprimé | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.